Peer Review History
| Original SubmissionMay 21, 2021 |
|---|
|
PONE-D-21-16747 Survey and Molecular Detection of Sri Lankan Cassava Mosaic Virus in Thailand PLOS ONE Dear Dr. Siriwan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 16 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Hanu R Pappu Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. In your Methods section, please provide additional information regarding the permits you obtained for the work. Please ensure you have included the full name of the authority that approved the field site access and, if no permits were required, a brief statement explaining why. 3. In your Methods section, please provide additional location information, including geographic coordinates for the data set if available. 4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. 5. Thank you for stating the following in the Acknowledgments Section of your manuscript: "This study was supported by the Center of Excellence on Agricultural Biotechnology, Science and Technology Postgraduate Education and Research Development Office, Office of Higher Education Commission, Ministry of Education (AG-BIO/PERDO-CHE) and Thai Tapioca Development Institute (TTDI), Thailand." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The authors received no specific funding for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 6. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Abstract: “Cassava plantations in an area of 458 ha spanning five province….” do not use unit abbreviations in abstract. “Disease severity was generally scored as 2–3….” Based on which scale? Mention either disease severity index value or disease incidence. “Prachinburi but was sparse in Surin, with the largest populations observed in May and June…” Mention year with months. Materials and Methods section describes more about disease incidence and its prevalence. The author has used formulas from incidence and prevalence to assess the disease score. However, the “SLCMV prevalence and symptom severity” heading under result section is focusing on the data based on disease severity index (DSI) and prevalence. It is better to add DSI formula under the materials and methods. Further use separate heading for DSI data under result section. Author should provide supplementary data including gel images for PCR based detection of CMV. Page 11. “At the first inspection, we found four plants infected by stem cuttings; in the second visit, 10 plants show CMD symptoms on the top 4–6 leaves; and in the last inspection, 15 plants were infected by whiteflies. This phenomenon was observed not only in Surin but also in other provinces included in the survey….” Provide supplementary data including images or pictures collected for this CMD infection on leaves. Overall, there are minor grammatical problems throughout the manuscript. Read the manuscript thoroughly before re-submission. Reviewer #2: Abstract: Sentence 7 should read: In 95% of cases, the infection was due to virus transmission by whitefly…….. Sentence 9: “Furthermore, the AV1 gene ………….” Please clarify the AV1 gene of which virus? Background: Paragraph 1: The first sentence needs to be referenced. It’s not clear from the last sentence in the paragraph whether the export value of 2.66 billion USD refers to Thailand. Paragraph 2: The first sentence is not clearly expressed. It can be changed to read “ Cassava mosaic disease (CMD) caused by cassava mosaic geminivirus (CMV) is one of the most important diseases in Africa with CMV being among the top 10 viruses affecting economically important crops.” The second sentence must be followed by the fourth sentence. The authors must then say something about the genome size of CMV. In sentence 5, authors must state the mode of transmission of the virus by whitefly. Last sentence: Replace word “including” with a semi-colon. Indian cassava mosaic virus must be followed by virus acronym in brackets. Paragraph 3: The first sentence does not make sense. CMD emerged 2016-2017 after being reported in North East Cambodia in 2015! This disparity needs to be reconciled Materials and Methods: A map to show the areas survey will be good. DNA extraction and SLCMV detection: It is not clear whether the PCR thermal cycling conditions described are for detecting the SLCMV AV1 gene or the whitefly mtCO1 gene. Authors must differentiate between the conditions for the two genes. Complete genome characterization of the SLCMV isolate ….. The authors must explain why the Burian province isolate was selected as the representative sample for whole genome sequencing. Results: SLCMV diagnosis and symptom analysis: First sentence: The Supplementary table S1 is showing primer sequences not survey data as stated in the first sentence. This needs to be corrected. Second paragraph: Authors can show pictures of the difference between cutting-borne and whitefly-borne symptoms. A picture speaks a thousand words. Third paragraph: The whole paragraph needs to be re-written. It is not clearly explained how the authors determined that the first symptoms were due to cutting-borne infections and the later ones were due to white-borne infections. Assessment of whitefly population size: Paragraph 2: Authors need to explain what they mean by “two month old plants facilitated whitefly counting” Discussion: Paragraph 1: First sentence should read: “We surveyed for CMD incidence and whitefly population in an area where CMD had previously been reported…….” Paragraph 2: Second sentence should read: “Steng Teng is situated approximately ………” Paragraph 6: First sentence is stating the very obvious. What is the point the authors are making here? Reviewer #3: Specific comments Page 16: “SLCMV prevalence and symptom severity”. Authors have carried out PCR diagnoses for the presence of viruses in their field-collected samples. They have used pair of primer specific for SLCMV. However, PCR with SLCMV specific primer could also amplify other closely related begomoviruses. Wondering, how do they rule out this? Page 19: “Whole-genome sequence of SLCMV”. Out of 6120 samples collected from different provinces, they have detected the presence of SLCMV in 1434 samples by PCR using AV1-specific primers. Later, the authors have mentioned that they have cloned and sequenced full-length viral genome. How many full-length viruses did they cloned and sequenced? How many samples did they choose for each province for full-length virus cloning and sequencing? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Survey and Molecular Detection of Sri Lankan Cassava Mosaic Virus in Thailand PONE-D-21-16747R1 Dear Dr. Siriwan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Hanu R Pappu Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-16747R1 Survey and Molecular Detection of Sri Lankan Cassava Mosaic Virus in Thailand Dear Dr. Siriwan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Hanu R Pappu Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .